Yang Liu1, Huan Lu2, Wei Wang3, Qi Liu4, Changju Zhu4. 1. Department of Radiotherapy Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital , Henan, China. 2. Department of Anesthesia and Intensive Care, Fudan University Shanghai Cancer Center , Shanghai, China. 3. Department of Clinical Evaluation, Henan Medical Association , Zhengzhou, Henan, China. 4. Department of Emergency Intensive Care, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, Henan, China.
Abstract
INTRODUCTION: Patients with cancer are more vulnerable to COVID-19 than the general population. Accordingly, it is necessary to identify the risk factors for death in patients with cancer and COVID-19. METHODS: PubMed, Cochrane Library, and Embase Ovid databases were searched for relevant articles published before July 31st, 2020. Studies that explored the risk factors for mortality were included. The effect size was relative risk (RR) and 95% confidence interval (CI). RESULTS: We included 17 observational studies involving 3268 patients. The pooled mortality was 24.8%. Male gender, age above 65 years, and comorbidities (especially hypertension and COPD) were risk factors for death (RR 1.16, 1.27, 1.12; 95% CI 0.7-1.95, 1.08-1.49, 1.04-1.2; P = 0.006, 0.004, and 0.002, respectively). Recent anti-cancer treatments did not increase mortality (P > 0.05). Dyspnea, cough, and sputum canused an elevated risk of death (P < 0.05). Antibiotics, glucocorticoids, interferons, invasive ventilation, and complications were associated with a high probability of death (P < 0.05). CONCLUSIONS: Various demographic and clinical characteristics, such as male gender, advanced age, comorbidities, and symptoms, were risk factors for mortality in patients with cancer and COVID-19. Our findings suggest recent anti-cancer treatments do not increase mortality.
INTRODUCTION:Patients with cancer are more vulnerable to COVID-19 than the general population. Accordingly, it is necessary to identify the risk factors for death in patients with cancer and COVID-19. METHODS: PubMed, Cochrane Library, and Embase Ovid databases were searched for relevant articles published before July 31st, 2020. Studies that explored the risk factors for mortality were included. The effect size was relative risk (RR) and 95% confidence interval (CI). RESULTS: We included 17 observational studies involving 3268 patients. The pooled mortality was 24.8%. Male gender, age above 65 years, and comorbidities (especially hypertension and COPD) were risk factors for death (RR 1.16, 1.27, 1.12; 95% CI 0.7-1.95, 1.08-1.49, 1.04-1.2; P = 0.006, 0.004, and 0.002, respectively). Recent anti-cancer treatments did not increase mortality (P > 0.05). Dyspnea, cough, and sputum canused an elevated risk of death (P < 0.05). Antibiotics, glucocorticoids, interferons, invasive ventilation, and complications were associated with a high probability of death (P < 0.05). CONCLUSIONS: Various demographic and clinical characteristics, such as male gender, advanced age, comorbidities, and symptoms, were risk factors for mortality in patients with cancer and COVID-19. Our findings suggest recent anti-cancer treatments do not increase mortality.
Authors: Joshua W Bliss; Jessica A Lavery; Whitney P Underwood; Su S Chun; Gina A Fickera; Catherine P Lee; Stacie Corcoran; Molly A Maloy; Fernanda C Polubriaginof; Daniel W Kelly; Jessica M Scott; Paul C Boutros; Chaya S Moskowitz; Lee W Jones Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-05-04 Impact factor: 4.090
Authors: Marina Treskova-Schwarzbach; Laura Haas; Sarah Reda; Antonia Pilic; Anna Borodova; Kasra Karimi; Judith Koch; Teresa Nygren; Stefan Scholz; Viktoria Schönfeld; Sabine Vygen-Bonnet; Ole Wichmann; Thomas Harder Journal: BMC Med Date: 2021-08-27 Impact factor: 8.775
Authors: Livia Costa de Oliveira; Karla Santos da Costa Rosa; Alessandra Zanei Borsatto; Luciana Aparecida Faria de Oliveira; Renata de Freitas; Simone Garruth Dos Santos Machado Sampaio Journal: Support Care Cancer Date: 2021-03-29 Impact factor: 3.603
Authors: Marc De Hert; Victor Mazereel; Marc Stroobants; Livia De Picker; Kristof Van Assche; Johan Detraux Journal: Front Psychiatry Date: 2022-01-13 Impact factor: 4.157